Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34270825/

doi: 10.1111/ejh.13690. Online ahead of print. 1 Medizinische Klinik, München Klinik Schwabing, Munich, Germany. 2 Asklepios Tumorzentrum Hamburg, AK Altona und AK St. Georg, Hamburg, Germany. 3 Medizinische Klinik und...

Trying to stomach multiple myeloma: A case report - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34123929/

We report a case of a 51-year-old male with minimal past medical history who presented to his primary care provider with nausea, vomiting and constipation in the outpatient setting. Concomitantly,...

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34131635/

Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with...

Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34133718/

Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic...

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34134766/

doi: 10.1186/s40364-021-00296-7. 1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. 3 Department of...